Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS).


Solabegron has completed and demonstrated positive results in initial Phase II clinical studies for the treatment of overactive bladder (OAB) in women and irritable bowel syndrome (IBS).


Velicept Therapeutics Initiates First of Two Phase 2b Dose-Ranging Studies of Solabegron in Patients with Overactive Bladder (OAB); Finalizes Novel, Once Daily Formulation; and Receives U.S. Patent Covering OAB

-First study has begun enrolling patients to evaluate twice-daily formulation- -Second study to begin in the second quarter to assess once-daily dosing with the novel QD formulation- -Issuance of U.S. Patent No. 9,907,767 further expands Velicept’s patent portfolio covering Solabegron- MALVERN, PA – March 19, 2018 – Velicept Therapeutics, a privately-held specialty pharmaceutical company dedicated […]